About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Oncology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
C
2020 ASCO Update on Selinexor in R/R Multiple Myeloma: Does a Weekly 100 mg Dosing + Daratumumab/Dexamethasone Produce Deep and Durable Response?
By
Cristina Gasparetto
3 Videos
June 25, 2020
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Scripps MD Anderson Cancer Center
Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology 2021
Sat, Feb 20, 2021
The Royal Marsden School
Demystifying the Science Behind Targeted Treatments for Haematological C...
Tue, Feb 2, 2021
Total Health Conferencing
Virtual West Oncology Conference
Fri, Feb 26, 2021
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...
Feat.
T. Martin
14:16
2nd SOHO Italian Conference
2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do T...
Feat.
K. Anderson
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
26:18
Morie Gertz
Treatment of Relapsed Myeloma: Overview of Approved Drugs, mSMART Classi...
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...
Feat.
J. Berdeja
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...
Feat.
M. Dimopoulos
12:03
Andrew Cowan
BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...
09:50
Nina Shah
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...
19:41
Peter Voorhees
Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...
06:12
Indy Hematology Review
Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...
Feat.
K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...
Feat.
S. Jagannath
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...
Feat.
S. Lonial
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myeloma
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...
Feat.
A. Rosko
08:25
Cristina Gasparetto
2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...
19:43
2020 ASCO Virtual Directâ„¢ Highlights
2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Di...
Feat.
R. Vij
12:32
Indy Hematology Review
What's New in Immunotherapy and Genomics in Multiple Myeloma?
Feat.
K. Anderson
09:02
Maria-Victoria Mateos
FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma